Inhibitory Effect of the D(3) Dopamine Receptor on Insulin Receptor Expression and Function in Vascular Smooth Muscle Cells

Overview

Journal Am J Hypertens

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2011 Mar 19

PMID 21415841

Citations 8

Authors

Hefei Huang

Yu Han

Xiaoyan Wang

Caiyu Chen

Changqing Yu

Duofen He

Hongyong Wang

Lin Zhou

Laureano D Asico

Pedro A Jose

Chunyu Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Vascular smooth muscle cell (VSMC) proliferation is regulated by numerous hormones and humoral factors. Our previous study found that stimulation of D(1)-like dopamine receptors inhibited insulin receptor expression and function in VSMCs. We hypothesize that there is also an interaction between D(3) dopamine and insulin receptors, i.e., stimulation of the D(3) receptor inhibits insulin receptor expression and function.

Methods: Receptor expression was determined by immunoblotting, immunohistochemisty, and reverse transcriptase-PCR; VSMC proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-diphenyl-tetrazolium bromide (MTT) assay and cell number.

Results: Insulin receptor protein is increased in the aorta of D(3) receptor deficient mice. Stimulation of the D(3) receptor inhibited insulin receptor mRNA and protein expression and insulin-mediated VSMC proliferation, and increased protein kinase A (PKA) activity, insulin receptor phosphorylation, and degradation in immortalized aortic VSMCs (A10 cells). These effects were blocked by a PKA inhibitor, indicating that the D(3) receptor-mediated decrease in insulin receptor expression was related to a decrease in transcription/post-transcription and increased degradation, involving PKA signaling.

Conclusions: D(3) receptor stimulation may be a target to reduce the adverse effect of insulin in hypertension by inhibition of insulin receptor expression and function in arterial VSMCs.

Citing Articles

Resveratrol Inhibits Insulin-Induced Vascular Smooth Muscle Cell Proliferation and Migration by Activating SIRT1.

Wang Y, Lei L, Su Q, Qin S, Zhong J, Ni Y Evid Based Complement Alternat Med. 2022; 2022:8537881.

PMID: 36479179 PMC: 9722291. DOI: 10.1155/2022/8537881.

Editorial: Role of Molecular Modulators in Combatting Cardiac Injury and Disease: Prevention, Repair and Regeneration.

de Castro Bras L, Schibalski R, Ilatovskaya D, OMeara C, DeLeon-Pennell K Front Cardiovasc Med. 2022; 9:861442.

PMID: 35509270 PMC: 9058098. DOI: 10.3389/fcvm.2022.861442.

Loss of Function in Dopamine D3 Receptor Attenuates Left Ventricular Cardiac Fibroblast Migration and Proliferation .

Kisling A, Byrne S, Parekh R, Melit-Thomas D, de Castro Bras L, Lust R Front Cardiovasc Med. 2021; 8:732282.

PMID: 34708087 PMC: 8542768. DOI: 10.3389/fcvm.2021.732282.

Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta.

Zingales V, Torrisi S, Leggio G, Bucolo C, Drago F, Salomone S Biomolecules. 2021; 11(3).

PMID: 33799860 PMC: 8001456. DOI: 10.3390/biom11030418.

Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis.

Yu Z, Jiang H, Shao L, Zhou Y, Shi H, Ruan B Br J Clin Pharmacol. 2016; 82(3):624-32.

PMID: 27198162 PMC: 5338104. DOI: 10.1111/bcp.12985.

References

Sonalker P, Jackson E . Norepinephrine, via beta-adrenoceptors, regulates bumetanide-sensitive cotransporter type 1 expression in thick ascending limb cells. Hypertension. 2007; 49(6):1351-7. DOI: 10.1161/HYPERTENSIONAHA.107.088732. View

Asico L, Ladines C, Fuchs S, Accili D, Carey R, Semeraro C . Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest. 1998; 102(3):493-8. PMC: 508909. DOI: 10.1172/JCI3685. View

Banday A, Asghar M, Hussain T, Lokhandwala M . Dopamine-mediated inhibition of renal Na,K-ATPase is reduced by insulin. Hypertension. 2003; 41(6):1353-8. DOI: 10.1161/01.HYP.0000069260.11830.CD. View

Bobalova J, Mutafova-Yambolieva V . Activation of the adenylyl cyclase/protein kinase A pathway facilitates neural release of beta-nicotinamide adenine dinucleotide in canine mesenteric artery. Eur J Pharmacol. 2006; 536(1-2):128-32. DOI: 10.1016/j.ejphar.2006.02.049. View

Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H, Baba H . Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res. 2010; 8(8):1152-63. DOI: 10.1158/1541-7786.MCR-09-0472. View

Curran M, Robinson D, Keating G . Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications. Drugs. 2006; 66(13):1755-82. DOI: 10.2165/00003495-200666130-00010. View

Krook A, Zierath J . Specificity of insulin signalling in human skeletal muscle as revealed by small interfering RNA. Diabetologia. 2009; 52(7):1231-9. DOI: 10.1007/s00125-009-1330-y. View

Zeng C, Wang D, Yang Z, Wang Z, Asico L, Wilcox C . Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension. 2004; 43(3):673-9. DOI: 10.1161/01.HYP.0000118958.27649.6f. View

Zeng C, Armando I, Luo Y, Eisner G, Felder R, Jose P . Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol. 2007; 294(2):H551-69. PMC: 4029502. DOI: 10.1152/ajpheart.01036.2007. View

10.

Fetalvero K, Shyu M, Nomikos A, Chiu Y, Wagner R, Powell R . The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol. 2006; 290(4):H1337-46. DOI: 10.1152/ajpheart.00936.2005. View

11.

Cincotta A, Meier A, Cincotta Jr M . Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 2001; 8(10):1683-1707. DOI: 10.1517/13543784.8.10.1683. View

12.

Nigro J, Osman N, Dart A, Little P . Insulin resistance and atherosclerosis. Endocr Rev. 2006; 27(3):242-59. DOI: 10.1210/er.2005-0007. View

13.

Obadiah J, Avidor-Reiss T, Fishburn C, Carmon S, Bayewitch M, Vogel Z . Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. Cell Mol Neurobiol. 1999; 19(5):653-64. PMC: 11545430. DOI: 10.1023/a:1006988603199. View

14.

Kok P, Roelfsema F, Frolich M, van Pelt J, Stokkel M, Meinders A . Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006; 291(5):E1038-43. DOI: 10.1152/ajpendo.00567.2005. View

15.

Zhang Y, Cincotta A . Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation. Atherosclerosis. 1997; 133(1):37-44. DOI: 10.1016/s0021-9150(97)00113-5. View

16.

Marwaha A, Lokhandwala M . Diminished natriuretic response to dopamine D1 receptor agonist, SKF-38393 in obese Zucker rats. Clin Exp Hypertens. 2003; 25(8):509-15. DOI: 10.1081/ceh-120025334. View

17.

Zeng C, Liu Y, Wang Z, He D, Huang L, Yu P . Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res. 2006; 99(5):494-500. DOI: 10.1161/01.RES.0000240500.96746.ec. View

18.

Stadtmauer L, Rosen O . Increasing the cAMP content of IM-9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. J Biol Chem. 1986; 261(7):3402-7. View

19.

Umrani D, Goyal R . Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats. Clin Exp Hypertens. 2003; 25(4):221-33. DOI: 10.1081/ceh-120020392. View

20.

Li Z, Yu C, Han Y, Ren H, Shi W, Fu C . Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2008; 294(6):H2761-8. PMC: 2772091. DOI: 10.1152/ajpheart.01344.2007. View